The US-China Business Council has considered curbs on outward investments as detrimental to the resilience and flexibility of American companies and if they are implemented through a federal oversight panel, it might coerce and pressurize American investors into disclosing investments in sectors such as pharmaceuticals, semiconductors and batteries in China.